Dr Mark Cooksey – CEO & Managing Director – ABx Group (ASX:ABX) is a uniquely positioned, Australian company delivering materials for a cleaner future. The two current areas of focus are the creation of an ionic adsorption clay rare earth project in northern Tasmania and the establishment of a plant to produce hydrogen fluoride and aluminium fluoride from recycled industrial waste, to replace imports (ALCORE).
Copyright 2024 – Finance News Network
08 Jul 2021 - ImpediMed Limited (ASX:IPD) CEO and Managing Director Richard Carreon discusses the company's bioimpedance spectroscopy platform SOZO, which is particularly targeted at noninvasive clinical assessment and monitoring of fluid status and tissue composition in the treatment of secondary lymphoedema, heart failure and renal failure.
24 Jan 2024 - Investment expert Winston Sammut discusses recent M&A activity in the property sector, analyzing BWP Trust's bid for Newmarket and Aspen's offer for Eureka Holdings. Sammut shares insights on deal rationale, pricing concerns, and potential market implications.
06 May 2020 - Acorn Capital Investment Fund Ltd. (ASX: ACQ) Head of Research and Portfolio Manager for the Consumer Discretionary, Consumer Staples and Information Technology sectors, Robert Bruce talks about the listed investment company, the fund’s composition and outlook for the next 6 months and longer term.
05 Nov 2021 - BrainChip Holdings Limited (ASX:BRN) Vice President of Worldwide Sales and Marketing Rob Telson talks about the company and the future of artificial intelligence.
30 Jul 2021 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, provides an update on activities from the company's June quarter, discussing growth in platforms and infrastructure and the recent capital raise.
09 Dec 2020 - Alterity Therapeutics Limited (ASX:ATH) Chairman and CEO Geoffrey Kempler provides an update on the company's lead compound ATH434 for Multiple System Atrophy, its dual strategy in Europe and the US and its Phase 2 plans.
21 Mar 2021 - Elixinol Global (ASX:EXL) CEO, Oliver Horn talks about its proposed acquisition of CannaCare Health GmbH (CannaCare) one of Germany’s leading CBD (Cannabidiol) brands following the down scheduling of CBD in Europe late last year in what the Company sees as highly strategic opportunity and important pathway to profitability.
